In this experiment, the rumen microbiota of healthy cows, cows with left-displaced abomasum (LDA), and cows after 7 days of LDA treatment (LDA_7) were compared to explore the correlation between LDA and the rumen microbiota and identify early warning markers for LDA. Compared with the healthy group and the LDA_7 group, the LDA group exhibited fewer Operational Taxonomic Units (LDA: 21,361; Healthy: 23,231; LDA_7: 23,956; p < 0.05). The results revealed significant differences in community structure between LDA-affected cows and healthy cows, as well as between treated and untreated LDA-affected cows. Specifically, the relative abundance of Bacteroidota significantly increased and the relative abundance of Firmicutes significantly decreased in LDA-affected cows (p < 0.05). At the genus level, the abundances of UCG_002, UCG_010, and Bacteroidales_BS11_gut_group significantly increased (p < 0.01), whereas those of Trichosporon, Chryseomicrobium, and [Ruminococcus]_gauvreauii_group significantly decreased in LDA-affected cows (p < 0.01). Functional prediction analysis indicated that amino acid biosynthesis and glycerol ester metabolism were significantly downregulated in LDA-affected cows (p < 0.01). After treatment, the abundance of key microbial taxa (UCG_002 and Lachnospira) and metabolic functions normalized to levels similar to healthy cows (p > 0.05). These findings suggest that changes in rumen microbiota richness and diversity could serve as early warning markers for LDA detection.
Bovine norovirus (BNoV) can cause acute diarrhea in calves and is highly contagious. Currently, no clinically effective therapeutic drugs are available, and vaccination is one of the most effective measures for controlling this infectious disease. In this study, a recombinant multi-epitope vaccine was constructed using a molecular adjuvant fusion design. In vitro safety assays showed that the recombinant protein at various concentrations exhibited no significant cytotoxicity to cells, and in vivo assessments indicated that the vaccine caused no pathological damage to major organs and induced no hemolytic reactions in experimental animals. The immunogenicity evaluation showed that the vaccine specifically induced high-titer IgG antibodies, significantly increased Th1-type cytokine levels, promoted splenocyte proliferation, and activated specific cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL); moreover, it increased the proportion of CD4+ and CD8+ T cells. In conclusion, the recombinant protein vaccine developed in this study exhibited a satisfactory safety profile and elicited robust IgG and related cellular immune responses, providing important experimental evidence for the further development of a bovine norovirus vaccine.
To prevent the spread of antibiotic resistance, bacteriophages have gradually become the most promising alternative to antibiotics for treating bacterial infectious diseases. In this study, using E. coli DC1 as the host strain, we isolated a bacteriophage named Escherichia coli phage XJA18 from farm sewage. We conducted morphological identification, host range determination, biological characteristic analysis, genomic feature analysis, and evaluation of in vitro and in vivo antibacterial effects. Electron microscopy revealed that phage XJA18 belongs to the class Caudoviricetes, with an icosahedral head and a non-contractile long tail. Whole-genome sequencing revealed that the phage has dsDNA with a length of 50,572 bp, with a GC content of 45.33%. The genome does not contain any antibiotic resistance genes or virulence genes, indicating good safety. XJA18 showed lytic activity against 24% of clinically isolated E. coli strains. The optimal multiplicity of infection (MOI) was 0.001, with a latent period of 10 min, a burst period of 30 min, and a burst size of 2.22 × 102 PFU/cell. It remained stable at 4–50 °C and pH 4–12. In vitro antibacterial results revealed that XJA18 had the most pronounced initial bacterial growth suppression at MOI = 0.001 during the first 4 h. In vivo experiments demonstrated that both prophylactic and therapeutic administration of XJA18 could protect against E. coli infection, significantly reducing inflammatory cytokine levels and bacterial loads in the livers and spleens of mice (p < 0.001), significantly increasing body weight (p < 0.05), and reducing histopathological damage to the colon, liver, and lungs. In summary, phage XJA18 can effectively inhibit E. coli and is safe and stable. These characteristics indicate that phage XJA18 has great potential as a novel biological agent to replace antibiotics for treating bacterial infectious diarrhea in calves.